Gesynta Pharma reports positive results for GS-248 phase 1 study
Swedish pharma company Gesynta Pharma has reported positive results from the phase 1 clinical trial of GS-248, which is being developed for the treatment of microvascular diseases in chronic inflammatory conditions. The purpose of the early-stage clinical trial was to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of GS-248 after subjecting healthy subjects to […]
NeuroVive completes enrollment in KL1333 clinical trial for mitochondrial disease
December 23, 2019 No Comment
KL1333 clinical trial : Swedish biotech company NeuroVive Pharmaceutical has wrapped up recruitment of healthy volunteers in the second part of its ongoing phase Ia/b clinical trial for its drug candidate drug KL1333 for the chronic oral treatment of primary mitochondrial disease. According to NeuroVive Pharmaceutical, the first part of the clinical study assessed the […]
Continue reading …
Recipharm acquisition of Consort Medical : Swedish pharma group Recipharm has agreed to acquire Consort Medical, a British contract development and manufacturing organization (CDMO) for £505 million, as per the latest pharma acquisition news. The transaction is said to help Recipharm become a major inhalation company and places it among the top five CDMO players […]
Continue reading …
Sobi acquisition of Dova Pharmaceuticals : Swedish Orphan Biovitrum (Sobi) has signed a deal worth up to $915 million to acquire Dova Pharmaceuticals, a US pharma company, in a move to become a major player in hematology and orphan diseases and also for expanding its footprint in the US. Shareholders of Dova Pharmaceuticals will be […]
Continue reading …
T20K MS clinical trial : Swedish biotech company Cyxone said that a phase 1 clinical trial for its drug candidate T20K for multiple sclerosis (MS) has confirmed its safety and tolerability in humans. Cyxone said that there were no serious adverse events in the early-stage infusion study. As the next step in its development program, […]
Continue reading …Calliditas initiates NEFIGARD trial to study Nefecon in Berger’s disease
November 14, 2018 No Comment
Nefecon phase 3 trial : Calliditas Therapeutics has initiated a phase 3 clinical trial called NEFIGARD to evaluate its lead candidate Nefecon for the treatment of IgA nephropathy (IgAN), which is also known as Berger’s disease. Phase 3 NEFIGARD trial of Nefecon The Swedish pharma company has enrolled the first patient for the late-stage NEFIGARD […]
Continue reading …Sickle cell disease drug developer Modus Therapeutics raises $16m in new funding
July 15, 2018 No Comment
Modus Therapeutics, a Swedish biotech company focused on developing sickle cell disease drugs, has raised SEK 140 million ($15.76 million) in a funding round led by new investor HealthCap, a European venture capital firm. HealthCap, which makes investments in breakthrough therapies of diseases with highly unmet medical needs, had injected SEK 60 million ($6.75 million) […]
Continue reading …
Business News Today
- Delivery Hero to acquire Latin American business of Glovo in €230m deal
- Amazon India opens two new fulfilment centres in Hyderabad
- Volansi bags $50m in Series B round for middle-mile drone delivery services
- British clothing retailer Next to form JV with Victoria’s Secret UK
- Cocomels launches new Sugar Free Coconut Milk Caramels
- Verizon to acquire US prepaid wireless provider Tracfone Wireless from America Movil
- NVIDIA to acquire British chip designer Arm from SoftBank for $40bn
- Neptune Energy gets NPD nod for drilling 6406/12-G-1 H well in PL 586
- Seattle Genetics signs $4.4bn worth oncology deals with Merck
- Gilead acquisition of Immunomedics : Pharma giant to gain access to breast cancer drug Trodelvy
